Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes

N Plevris,G R Jones,P Jenkinson,Mathew Lyons,C S Chuah,Lynne Merchant,Rebecca Pattenden,E Watson,Gwo-Tzer Ho,Colin L. Noble,S Din,Alan G. Shand,Ian D. Arnott,Charlie W. Lees

Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes

2018

N Plevris
G R Jones
P Jenkinson
Mathew Lyons
C S Chuah
Lynne Merchant
Rebecca Pattenden
E Watson
Gwo-Tzer Ho
Colin L. Noble
S Din
Alan G. Shand
Ian D. Arnott
Charlie W. Lees

Background Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn’s disease.

Keywords:

Biosimilar
Diabetes mellitus
Medicine
Endocrinology
Internal medicine
Pediatrics
Infliximab
Disease
Crohn's disease
Cohort
Adverse effect
Hepatology
Faecal calprotectin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations